Skip to content
    Oncology Data Advisor Logo

    iCAD: Creating a World Where Cancer Can’t Hide With Waqas Haque, MD, MPH, and Dana Brown

    Expert Perspectives

    By Keira Smith

    Published

    In this episode of Exploring Artificial Intelligence (AI) in Oncology, Dr. Waqas Haque sits down with Dana Brown, the President, CEO, and Chairman of the Board at iCAD, a company whose mission is to use innovative AI solutions that empower providers to accurately, reliably, and quickly detect cancer and improve outcomes. Ms. Brown shares more about iCAD’s products and recommendations for how to integrate AI into the clinic, including:

    • Her own background in the technology industry and why she joined iCAD
    • The products and solutions that iCAD offers
    • How iCAD utilizes AI to improve mammography accuracy
    • The ProFound Breast Health Suite and how it enhances cancer detection and patient outcomes
    • Their recent partnership with Densitas and CancerIQ and their impact on breast health
    • What distinguishes iCAD’s AI algorithms from other solutions in the market
    • The importance of company culture in driving success of AI startups and defining traits behind iCAD’s success
    • Recommendations for clinicians in practice to learn about and integrate AI into their workflow
    • And more!

    About Dana Brown and Waqas Haque

    Dana Brown is the President, CEO, and Chairman of the Board at iCAD. Previously, she was the Senior Vice President and Chief Strategy and Operations Officer at Susan G. Komen. She was also previously the Senior Vice President and Chief Digital Officer at United Way Worldwide. Ms. Brown has more than 30 years of experience in the technology industry.

    Waqas Haque, MD, MPH, is a Hematology/Oncology Fellow at the University of Chicago. He recently completed his Internal Medicine Residency at New York University (NYU) in a Clinical Investigator Track. Dr. Haque has balanced his patient care work with a variety of research projects. During his fellowship training at the University of Chicago, he plans to further his work in innovative clinical trial design, value-based care delivery to cancer patients, and clinical investigation.